Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
NCT ID: NCT03838926
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
42 participants
INTERVENTIONAL
2018-09-27
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
NCT00098514
AS703569 Phase I in Patients With Solid Tumours
NCT00391521
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
NCT01251562
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors
NCT00104286
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trichostatin A
Trichostatin A
Intravenous Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trichostatin A
Intravenous Infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
* Presence of measurable or evaluable disease;
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
* Contraceptives or other approved avoidance of pregnancy measures
Exclusion Criteria
* Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
* Undergone major surgery ≤ 2 weeks prior to starting study drug;
* Evidence of mucosal or internal bleeding;
* Impaired cardiac function or conduction defect;
* Concurrent severe and/or uncontrolled medical conditions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Washington D.C., District of Columbia, United States
Vanda Investigational Site
Lafayette, Indiana, United States
Vanda Investigational Site
Hackensack, New Jersey, United States
Vanda Investigational Site
Seattle, Washington, United States
Vanda Investigational Site
Biała Podlaska, , Poland
Vanda Investigational Site
Katowice, , Poland
Vanda Investigational Site
Krakow, , Poland
Vanda Investigational Site
Opole, , Poland
Vanda Investigational Site
Skorzewo, , Poland
Vanda Investigational Site
Warsaw, , Poland
Vanda Investigational Site
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Vanda Pharmaceuticals
Role: primary
Vanda Pharmaceuticals
Role: primary
Vanda Pharmaceuticals
Role: primary
Vanda Pharmaceuticals
Role: primary
Vanda Pharmaceuticals
Role: primary
Vanda Pharmaceuticals
Role: primary
Vanda Pharmaceuticals
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VTR-297-1101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.